Approximately 15% of patients with invasive breast cancer are diagnosed with triple-negative breast cancer (TNBC), defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression (Foulkes et al., 2010). This evidence concerns the gene ERBB2 and invasive breast carcinoma.